Improving biomaterial scaffolds for regenerative medicine starts from identifying the most suitable materials based on their mechanical and physicochemical properties. Traditionally, a number of materials have been used in various scaffold configurations (polymers such as PLA, PGA and PLGA have been commonly used in assembling 3D constructs), and ongoing research efforts are advancing the development of scaffolds based on these as well as new material composites.
Chitosan, collagen and hyaluronic acid are not newcomers to the field of regenerative medicine, with their use having been reported in various applications, particularly in regenerative medicine. With that in mind, new studies on their use as scaffold constructs are building on that knowledge and contributing to a better understanding of these materials for tissue regeneration.
A new composite biomaterial based on blends of chitosan, collagen and hyaluronic acid was described in a new study by the lab of Dr. Tomasz Drewa at the Department of Regenerative Medicine at Nicolaus Copernicus University in Torun, Poland.
Titled “3D composites based on the blends of chitosan and collagen with the addition of hyaluronic acid,” the manuscript is published in the August 2016 issue of the International Journal of Biological Macromolecules.
The authors blended chitosan and collagen, and then supplemented the blended polymers by the addition of 1%, 2% and 5% of hyaluronic acid. Biological activity of the novel biomaterial composite was analyzed via the proliferation rate of fibroblasts incubated with the biomaterial scaffolds using an MTT assay. The authors observed good cell proliferation with no cytotoxicity, and postulated that the addition of hylarunoic acid was a positive addition to the scaffolds. Other assays included swelling behavior and thermal stability. Though positive, these are preliminary findings and further studies are needed to assert the in vivo performance of these scaffold blends.
Hyaluronic acid, owing to its favorable biomaterial properties that include favorable degradation profile, has in other studies been shown to be a suitable biomaterial for constructing scaffolds (Collins and Birkinshaw, 2013).
You can read the paper here.
Akron Biotech at ISCT 2016
Next week, Singapore hosts the 2016 Annual Meeting of the International Society for Cellular Therapy, which takes place May 25 – 28, 2016 at the Suntec Convention and Exhibition Centre in Singapore. Like previous years, Akron will be there, this time represented through a number of talks.
Akron’s CEO, Dr. Claudia Zylberberg, will participate and speak during two sessions.
The first will be during Quality and operations track 1 – Raw Materials Sourcing scheduled for Thursday, May 26th at 13:45 in Room 330. Dr. Zylberberg will give a talk titled “Raw Materials Regulations” which focuses on various regulatory, standardization and harmonization efforts, as well as optimal criteria when selecting raw materials for use in cell therapy product development.
Dr. Zylberberg will also chair the session Strategies for commercialization Track 8 – Ancillary materials from the user and supplier perspectives: advances and new approaches to reduce cost of goods, decrease risk, and enhance quality, which takes place on Saturday, May 28th in Room 335-336 from 13:15 – 14:45 with speakers that include Brian Newsom (Thermo Fisher Scientific), Jiwen Zhang (GE Healthcare) and Lynn Csontos (STEMCELL Technologies).
For more information about the ISCT Annual Meeting, please visit the official meeting website.
Akron will also be available for private meetings. Should you wish you schedule a private meeting, please contact us.